Absci Corporation

NasdaqGS:ABSI Aktierapport

Börsvärde: US$799.8m

Absci Framtida tillväxt

Future kriterier kontrolleras 2/6

Absci förväntas öka intäkter och intäkter med 5.3% respektive 45.7% per år. EPS förväntas tillväxt med 20% per år. Avkastningen på eget kapital förväntas bli -60.6% om 3 år.

Viktig information

5.3%

Tillväxttakt i vinsten

19.96%

Tillväxttakt för EPS

Biotechs vinsttillväxt25.2%
Intäkternas tillväxttakt45.7%
Framtida avkastning på eget kapital-60.60%
Bevakning av analytiker

Good

Senast uppdaterad14 May 2026

Senaste uppdateringarna om framtida tillväxt

Recent updates

Analysartikel • Apr 04

We Think Absci (NASDAQ:ABSI) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Jan 29

Absci Corporation: Drawing Potential Insights On ABS-101 And ABS-201

Summary Absci Corporation leverages AI for drug development, with clinical data already produced by ABS-101 and ahead for ABS-201 in 2026. ABS-101, an anti-TL1A antibody, might have fallen a little short of next-generation competitors in terms of half-life but might have advantages in other indications. ABS-201 has a competitor, HMI-115, that has performed in endometriosis and perhaps androgenetic alopecia. Read the full article on Seeking Alpha
Analysartikel • Jul 19

Does Absci (NASDAQ:ABSI) Have A Healthy Balance Sheet?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Jan 13

Absci Looks Cheap And Positioned For Growth With AMD's AI Backing

Summary Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. ABS-101 appears to be ABSI’s main drug candidate for IBD. However, ABS-201 for hair loss and ABS-301 for solid tumors offer additional sizeable TAMs if successful. ABSI’s AI models and wet lab data seem quite promising for discovering further antibodies that could be highly differentiated from other competitors. ABSI trades at a cheap P/B of 1.5, so I don’t think the shares have priced in the potential of its partnership with AMD yet. My main concern is that ABSI operates with highly speculative technologies, and its candidates remain in the early R&D stages. Read the full article on Seeking Alpha
Seeking Alpha • Nov 20

Absci Corporation: Struggling To Live Up To Its AI Promise

Summary Absci Corporation's stock has rebounded due to new collaborations, but skepticism about AI's impact on drug discovery keeps it heavily underwater from its IPO price. Absci uses AI and wet lab technologies to speed up drug discovery, aiming to reduce preclinical periods to under two years. Despite partnerships with Merck, AstraZeneca, and others, Absci's revenue remains minimal, and it has no advanced pipeline assets yet. With a market cap just over $300 million and cash runway into 1H27, Absci is a speculative play in the AI drug discovery space. An analysis around Absci Corporation follows in the paragraphs below. Read the full article on Seeking Alpha
Analysartikel • Nov 13

Is Absci (NASDAQ:ABSI) A Risky Investment?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha • Oct 29

Absci: Embryonic Pipeline Looks Expensive Relative To Peers

Summary Absci's differentiated drug discovery platform could create significant shareholder value long term. The company has a long and expensive path to traverse before it can prove the merits of its approach though. While cash burn is currently limited, Absci's operations are ramping, meaning increased costs could begin to pressure the share price in the future. Absci has largely avoided the growing pessimism towards AI-enabled drug discovery companies and is beginning to look expensive relative to peers as a result. Read the full article on Seeking Alpha
Seeking Alpha • Oct 03

Absci: AI-Driven Platform Could Establish Best-In-Class TL1A Drug Targeting Profile

Summary Absci Corporation's initiation of a phase 1 study using ABS-101 for the treatment of patients with IBD expected early 2025, with interim data to be released in the 2nd half of 2025. ABS-101 aims to differentiate itself with unique features like de novo antibody creation, multiparameter lead optimization, and reverse immunology, potentially offering superior potency and dosing flexibility. The global Crohn's Disease treatment market is expected to reach $17.80 billion by 2033. The ulcerative colitis treatment market is expected to reach $14.77 billion by 2033. Read the full article on Seeking Alpha
Seeking Alpha • Jul 28

Absci Corporation Leverages AI For Rapid Drug Discovery And Promising Partnerships

Summary Absci Corporation uses IDCP technology to quickly produce high-quality drug candidates in as little as six weeks, reducing costs and improving research success rates. The company has promising candidates in inflammatory bowel disease, dermatology, and immuno-oncology, attracting major partnerships with over $900 million in deal value and royalties. ABSI focuses on three therapeutic areas: inflammatory bowel disease, dermatology, and immuno-oncology. Investors should be aware of the high risks due to the speculative nature of AI-driven drug discovery and potential funding needs. Still, ABSI trades at a reasonable valuation, making it a sound speculative "buy" for investors aware of biotech's inherent risks. Read the full article on Seeking Alpha
Analysartikel • Jun 17

Is Absci (NASDAQ:ABSI) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • May 16

Absci: 'AI' Tag Keeping Company Afloat While Searching For Right Formula

Summary Absci Corporation, an AI-driven drug discovery company, has seen its share price plummet after its IPO in July 2021. Nearly all AI-driven drug discovery companies have struggled with overall share price performance since IPO. Absci's stock has been picking up - +250% across the past six months - thanks to investment in the sector, and a recently agreed partnership with AstraZeneca. Merck is another Big Pharma partner, but these deals don't guarantee revenues and with development programs preclinical, it's difficult to assign much value. Without its "AI" tag, Absci would likely be a $100m - $200m market cap valuation company. The company may show its mettle in time, but the prospect of near term revenues, or further upside, seems remote in 2024. Read the full article on Seeking Alpha
Seeking Alpha • Feb 27

Absci: Differentiated Antibody Discovery Play

Summary Absci combines generative AI with scalable wet lab technologies to improve antibody discovery, with the eventual goal of in silico drug design. While Absci's stock has benefitted from AI hype in recent months, the company has substance. Its approach to antibody drug development is unique and could have advantages. Absci's valuation is still reasonable given the company's long-term potential, but the stock price is likely to be tied to AI sentiment in the near term, creating downside risk. Read the full article on Seeking Alpha

Prognoser för vinst- och omsättningstillväxt

NasdaqGS:ABSI - Analytikernas framtida uppskattningar och tidigare finansiella data (USD Millions )
DatumIntäkterIntäkterFritt kassaflödeKassaflöde från rörelsenGenomsnittligt Antal analytiker
12/31/202842-109-127N/A5
12/31/202720-118-151-1299
12/31/20266-124-140-1099
3/31/20262-118-99-97N/A
12/31/20253-115-94-93N/A
9/30/20253-115-82-81N/A
6/30/20254-113-77-76N/A
3/31/20255-107-77-76N/A
12/31/20245-103-73-72N/A
9/30/20244-98-71-70N/A
6/30/20243-92-61-60N/A
3/31/20245-109-63-62N/A
12/31/20236-111-65-65N/A
9/30/20237-106-70-68N/A
6/30/20239-112-83-77N/A
3/31/20236-99-90-80N/A
12/31/20226-105-98-81N/A
9/30/20226-111-104-80N/A
6/30/20225-107-107-83N/A
3/31/20225-121-113-74N/A
12/31/20215-103-99-61N/A
9/30/20216-84-77-46N/A
6/30/20215-73-53-27N/A
3/31/20215-48-24-16N/A
12/31/20205-49-13-11N/A
12/31/20192-24N/A-6N/A

Analytiker Framtid Tillväxt Prognoser

Intäkter kontra sparande: ABSI förväntas förbli olönsam under de kommande 3 åren.

Resultat vs marknad: ABSI förväntas förbli olönsam under de kommande 3 åren.

Höga tillväxtresultat: ABSI förväntas förbli olönsam under de kommande 3 åren.

Intäkt vs marknad: ABSI s intäkter ( 45.7% per år) förväntas växa snabbare än US marknaden ( 11.7% per år).

Hög tillväxtintäkter: ABSI s intäkter ( 45.7% per år) förutspås växa snabbare än 20% per år.

Tillväxtprognoser för vinst per aktie

Framtida avkastning på eget kapital

Framtida ROE: ABSI förväntas bli olönsam om 3 år.

Upptäck tillväxtföretag

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/05/18 11:23
Aktiekurs vid dagens slut2026/05/15 00:00
Intäkter2026/03/31
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Absci Corporation bevakas av 13 analytiker. 9 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Michael RyskinBofA Global Research
Vamil DivanGuggenheim Securities, LLC
null nullGuggenheim Securities, LLC